TY - JOUR
T1 - Efficacy of UVA1 phototherapy in 230 patients with various skin diseases
AU - Rombold, Stephanie
AU - Lobisch, K.
AU - Katzer, K.
AU - Grazziotin, T. C.
AU - Ring, J.
AU - Eberlein, B.
PY - 2008/2
Y1 - 2008/2
N2 - Objective: Investigation of the efficacy of ultraviolet (UV) A1 phototherapy on atopic eczema, scleroderma, granuloma annulare, urticaria pigmentosa, prurigo nodularis, lichen sclerosus et atrophicus, T-cell lymphoma, keratosis lichenoides chronica, chronic urticaria and some rare, sclerosing skin diseases. Methods: The data of 230 patients treated with low-dose, medium-dose and high-dose UVA1 therapy during 6 years were retrospectively analysed. The mean single dose (J/cm2), the mean number of irradiations and the mean total dose (J/cm2) were evaluated. The efficacy of phototherapy was assessed by a grading scale and the number of patients was given in percentage for each group. Results: Good therapeutic effects of UVA1 therapy were shown in patients with atopic eczema, scleroderma, lichen sclerosus et atrophicus, keratosis lichenoides chronica, prurigo nodularis and with cutaneous T-cell lymphoma. Positive effects in some patients were seen in the urticaria pigmentosa and granuloma annulare group, no change to slight improvement was seen in most of the patients with rare, sclerosing skin diseases and no effect was seen in the chronic urticaria group. Conclusion: Besides topical and systemic therapy, UVA1 radiation is a good option of treatment in various skin diseases. It is one of the first-line treatments for several sclerotic diseases and it often improves pruritus considerably.
AB - Objective: Investigation of the efficacy of ultraviolet (UV) A1 phototherapy on atopic eczema, scleroderma, granuloma annulare, urticaria pigmentosa, prurigo nodularis, lichen sclerosus et atrophicus, T-cell lymphoma, keratosis lichenoides chronica, chronic urticaria and some rare, sclerosing skin diseases. Methods: The data of 230 patients treated with low-dose, medium-dose and high-dose UVA1 therapy during 6 years were retrospectively analysed. The mean single dose (J/cm2), the mean number of irradiations and the mean total dose (J/cm2) were evaluated. The efficacy of phototherapy was assessed by a grading scale and the number of patients was given in percentage for each group. Results: Good therapeutic effects of UVA1 therapy were shown in patients with atopic eczema, scleroderma, lichen sclerosus et atrophicus, keratosis lichenoides chronica, prurigo nodularis and with cutaneous T-cell lymphoma. Positive effects in some patients were seen in the urticaria pigmentosa and granuloma annulare group, no change to slight improvement was seen in most of the patients with rare, sclerosing skin diseases and no effect was seen in the chronic urticaria group. Conclusion: Besides topical and systemic therapy, UVA1 radiation is a good option of treatment in various skin diseases. It is one of the first-line treatments for several sclerotic diseases and it often improves pruritus considerably.
KW - Atopic eczema
KW - Phototherapy
KW - Scleroderma
KW - UVA1 therapy
UR - http://www.scopus.com/inward/record.url?scp=38349032842&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0781.2008.00328.x
DO - 10.1111/j.1600-0781.2008.00328.x
M3 - Article
C2 - 18201353
AN - SCOPUS:38349032842
SN - 0905-4383
VL - 24
SP - 19
EP - 23
JO - Photodermatology Photoimmunology and Photomedicine
JF - Photodermatology Photoimmunology and Photomedicine
IS - 1
ER -